Literature DB >> 11827168

Response of cancer cells to molecular interruption of the CK2 signal.

H Wang1, A Davis, S Yu, K Ahmed.   

Abstract

Protein kinase CK2 is one of the key cellular signals for cell survival, growth, and proliferation. It is has been observed to be elevated in various cancers that have been examined. Various observations suggest that moderate dysregulation of CK2 may profoundly influence the cell response. We have examined the effects of interfering with the CK2 signal in various cancer cell lines by employing antisense oligodeoxynucleotides (ODN) against the alpha and beta subunits of CK2. Our results demonstrate that antisense CK2-alpha and antisense CK2-beta ODNs markedly influence cell viability of these cancer cells in a dose and time-dependent manner. Antisense CK2-alpha was slightly more effective than antisense CK2-beta in most of the cells tested. The efficacy of the antisense ODN seemed to vary with the cell type; however, in all cases potent induction of apoptosis was observed. Significantly, the effects of the antisense ODN on the CK2 activity in the nuclear matrix were relatively small compared to the much stronger induction of apoptosis in cells. This suggests that modest downregulation of CK2 can evoke a much greater apoptotic response in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11827168

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  19 in total

Review 1.  Protein kinase CK2 and its role in cellular proliferation, development and pathology.

Authors:  B Guerra; O G Issinger
Journal:  Electrophoresis       Date:  1999-02       Impact factor: 3.535

2.  Isolation, sequencing, and disruption of the yeast CKA2 gene: casein kinase II is essential for viability in Saccharomyces cerevisiae.

Authors:  R Padmanabha; J L Chen-Wu; D E Hanna; C V Glover
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

3.  Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase IIalpha.

Authors:  M A Kelliher; D C Seldin; P Leder
Journal:  EMBO J       Date:  1996-10-01       Impact factor: 11.598

4.  Differential targeting of protein kinase CK2 to the nuclear matrix upon transient overexpression of its subunits.

Authors:  S Yu; A T Davis; C Guo; J E Green; K Ahmed
Journal:  J Cell Biochem       Date:  1999-07-01       Impact factor: 4.429

Review 5.  Protein kinase CK2 signal in neoplasia.

Authors:  S Tawfic; S Yu; H Wang; R Faust; A Davis; K Ahmed
Journal:  Histol Histopathol       Date:  2001-04       Impact factor: 2.303

6.  Cloning of cDNAs encoding the alpha and beta subunits of rat casein kinase 2 (CK-2): investigation of molecular regulation of CK-2 by androgens in rat ventral prostate.

Authors:  K Ahmed; A Davis; J Hanten; D Lambert; R S McIvor; S A Goueli
Journal:  Cell Mol Biol Res       Date:  1993

7.  Cell growth stimulation by EGF: inhibition through antisense-oligodeoxynucleotides demonstrates important role of casein kinase II.

Authors:  R Pepperkok; P Lorenz; R Jakobi; W Ansorge; W Pyerin
Journal:  Exp Cell Res       Date:  1991-12       Impact factor: 3.905

Review 8.  Oligodeoxynucleotides as inhibitors of gene expression: a review.

Authors:  C A Stein; J S Cohen
Journal:  Cancer Res       Date:  1988-05-15       Impact factor: 12.701

9.  Depletion of catalytic and regulatory subunits of protein kinase CK2 by antisense oligonucleotide treatment of neuroblastoma cells.

Authors:  L Ulloa; J Díaz-Nido; J Avila
Journal:  Cell Mol Neurobiol       Date:  1994-10       Impact factor: 5.046

Review 10.  Antisense approaches to cancer gene therapy.

Authors:  D Mercola; J S Cohen
Journal:  Cancer Gene Ther       Date:  1995-03       Impact factor: 5.987

View more
  34 in total

Review 1.  Emergence of protein kinase CK2 as a key target in cancer therapy.

Authors:  Janeen H Trembley; Zhong Chen; Gretchen Unger; Joel Slaton; Betsy T Kren; Carter Van Waes; Khalil Ahmed
Journal:  Biofactors       Date:  2010 May-Jun       Impact factor: 6.113

Review 2.  Protein kinase CK2: structure, regulation and role in cellular decisions of life and death.

Authors:  David W Litchfield
Journal:  Biochem J       Date:  2003-01-01       Impact factor: 3.857

3.  Modulation of death receptor-mediated apoptosis by CK2.

Authors:  Guixia Wang; Kashif A Ahmad; Khalil Ahmed
Journal:  Mol Cell Biochem       Date:  2005-06       Impact factor: 3.396

4.  Downregulation of CK2 induces apoptosis in cancer cells--a potential approach to cancer therapy.

Authors:  Guixia Wang; Gretchen Unger; Kashif A Ahmad; Joel W Slaton; Khalil Ahmed
Journal:  Mol Cell Biochem       Date:  2005-06       Impact factor: 3.396

5.  Expanding the chemical diversity of CK2 inhibitors.

Authors:  Renaud Prudent; Virginie Moucadel; Miriam López-Ramos; Samia Aci; Beatrice Laudet; Liliane Mouawad; Caroline Barette; Jacques Einhorn; Cathy Einhorn; Jean-Noel Denis; Gilles Bisson; Frédéric Schmidt; Sylvaine Roy; Laurence Lafanechere; Jean-Claude Florent; Claude Cochet
Journal:  Mol Cell Biochem       Date:  2008-06-18       Impact factor: 3.396

Review 6.  Protein kinase CK2--a key suppressor of apoptosis.

Authors:  Kashif A Ahmad; Guixia Wang; Gretchen Unger; Joel Slaton; Khalil Ahmed
Journal:  Adv Enzyme Regul       Date:  2008-04-30

7.  Impact of protein kinase CK2 on inhibitor of apoptosis proteins in prostate cancer cells.

Authors:  Guixia Wang; Kashif A Ahmad; Nathan H Harris; Khalil Ahmed
Journal:  Mol Cell Biochem       Date:  2008-06-24       Impact factor: 3.396

8.  CK2 phosphorylation of SAG at Thr10 regulates SAG stability, but not its E3 ligase activity.

Authors:  Hongbin He; Mingjia Tan; Deepika Pamarthy; Guixia Wang; Khalil Ahmed; Yi Sun
Journal:  Mol Cell Biochem       Date:  2006-07-28       Impact factor: 3.396

9.  B23 is a downstream target of polyamine-modulated CK2.

Authors:  Kathryn Lawson; Laura Larentowicz; Lisa Laury-Kleintop; Susan K Gilmour
Journal:  Mol Cell Biochem       Date:  2005-06       Impact factor: 3.396

Review 10.  Regulation of cellular proliferation in acute lymphoblastic leukemia by Casein Kinase II (CK2) and Ikaros.

Authors:  Chandrika Gowda; Chunhua Song; Malika Kapadia; Jonathon L Payne; Tommy Hu; Yali Ding; Sinisa Dovat
Journal:  Adv Biol Regul       Date:  2016-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.